News & Updates

Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
27 Jun 2022 byRoshini Claire Anthony

Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.

Response analysis further establishes tezepelumab benefit in severe uncontrolled asthma
27 Jun 2022
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022 byTristan Manalac

The use of biosimilars of infliximab (IFX) and adalimumab (ADA) is both safe and effective in children with inflammatory bowel disease (IBD), inducing high rates of failure-free survival with a low incidence of adverse events, according to a study presented at the 2022 Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN 2022).

Infliximab, adalimumab biosimilars effective, safe in paediatric IBD
27 Jun 2022
Diabetes, fertility treatment, family history up autism risk in infants
Diabetes, fertility treatment, family history up autism risk in infants
26 Jun 2022
Baricitinib delays, lowers frequency of flares in JIA
Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022 byRoshini Claire Anthony

In patients with juvenile idiopathic arthritis (JIA) with insufficient response to conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs), the JAK*1/2 selective inhibitor baricitinib reduced the frequency and delayed time to disease flares, according to a phase III trial presented at EULAR 2022.

Baricitinib delays, lowers frequency of flares in JIA
23 Jun 2022
NAFLD linked to heightened type 2 diabetes risk
NAFLD linked to heightened type 2 diabetes risk
22 Jun 2022

Children with nonalcoholic fatty liver disease (NAFLD) are at an increased risk of type 2 diabetes, a study reports. Other risk factors for T2D include severity of liver histology, body mass index, and female sex.

NAFLD linked to heightened type 2 diabetes risk
22 Jun 2022
Normal weight obesity in adolescents tied to cardiometabolic risk
Normal weight obesity in adolescents tied to cardiometabolic risk
21 Jun 2022

Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.

Normal weight obesity in adolescents tied to cardiometabolic risk
21 Jun 2022